Mylan sues over Prilosec OTC
Executive Summary
Procter & Gamble's Prilosec OTC is falsely represented as identical to AstraZeneca's prescription version of the proton pump inhibitor, Mylan alleges in a Manhattan federal court lawsuit. Mylan also recently submitted a study to FDA that the company asserts demonstrates OTC omeprazole is not bioequivalent to Prilosec. P&G maintains the Rx and OTC 20 mg formulations are the same. Mylan alleges P&G's claims will divert sales from its own generic omeprazole, which launched "at risk" in August (1"The Pink Sheet" Aug. 11, 2003, p. 11)...
You may also be interested in...
Mylan Launches Generic Omeprazole; Takes Risk For Purple Gold
Mylan's decision to launch the second generic version of AstraZeneca's Prilosec (omeprazole) could inject a new level of price competition into the proton pump inhibitor category
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.